Trial Profile
The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary) ; Chloroquine diphosphate; Colistimethate sodium; Hydroxychloroquine; Umifenovir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 01 Aug 2021 Primary endpoint (Viral nucleic acid test negative conversion rate) has been met according to the results published in the International Immunopharmacology
- 01 Aug 2021 Status changed from recruiting to completed.
- 01 Aug 2021 Results assessing efficacy and safety of favipiravir published in the International Immunopharmacology